Myomectomy Market Size (2024 - 2029)

The myomectomy market is projected to experience growth driven by the increasing prevalence of uterine fibroids and the adoption of technologically advanced surgical procedures. The market's expansion is supported by the rising demand for minimally invasive surgeries, which offer reduced complications and shorter hospital stays. Technological advancements, such as robotic and laparoscopic-assisted surgeries, are enhancing treatment efficiency and quality, further contributing to market growth. Strategic initiatives by market players, including product launches and mergers, are also expected to facilitate segmental growth. However, the high costs associated with new medical devices and potential procedural complications may pose challenges to market expansion.

Market Size of Myomectomy Industry

Myomectomy Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 0.64 Billion
Market Size (2029) USD 0.93 Billion
CAGR (2024 - 2029) 8.10 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Myomectomy Market Major Players

*Disclaimer: Major Players sorted in no particular order

Myomectomy Market Analysis

The Myomectomy Market size is estimated at USD 0.64 billion in 2024, and is expected to reach USD 0.93 billion by 2029, growing at a CAGR of 8.10% during the forecast period (2024-2029).

An increase in the number of patients suffering from uterine fibroids is anticipated to be the key factor contributing to the growth of the myomectomy market. According to an article published by the International Journal of Reproduction, Contraception, Obstetrics, and Gynecology in July 2022, a study conducted in India showed that the incidence of fibroids was most common in 31-40 years of age, which was around 34.9%. The most commonly observed symptom for uterine fibroids was abdominal lump (41%) and abnormal uterine bleeding (24.1%). The prevalence of submucosal fibroids was 38.6%, intramural fibroids 19.3%, submucosal polyp 14.5%, seedling fibroid 13.9%, and subserosal fibroid 10.2%. Additionally, a rise in minimally invasive surgical procedures due to fewer complications and reduced hospital stays is anticipated to boost the market growth. Technological advancements such as the rise in robotic and laparoscopic-assisted surgeries to deliver quality and efficient treatment may also contribute to the growth of the myomectomy market.

According to an article published by MIS Journal in December 2022, uterine fibroids are considered a common benign smooth muscle tumor of the uterus that affects almost 70% of women until menopause. Risk factors of uterine fibroids include ethnicity, parity, early menarche, late menopause, family history, obesity, and hypertension. The presence of uterine fibroids is rarely life-threatening. However, they are often associated with symptoms affecting the quality of life, such as abnormal bleeding, pelvic pain, and urinary tract problems. The article also stated that robotic myomectomy has many advantages in uterine fibroid removal, such as lower blood loss, fewer complications, and shorter hospital stays over open surgery. The advantages of the wristed instruments, three-dimensional vision, and the incorporation of correct surgical techniques also emphasize the benefits of the robotic-assisted approach in large and numerous cases. Thus, the high burden of uterine fibroids and the increasing advantages of technologically advanced myomectomy procedures are expected to boost market growth.

The strategic activities by the market players, such as product launches and mergers and acquisitions, are expected to contribute to segmental growth over the forecast period. For instance, in November 2022, Olympus announced the launch of the moresolution Power Morcellator, manufactured by TROKAMED GmbH and available in the United States through a distribution agreement with Olympus America Inc. The moresolution Morcellator was designed for advanced gynecologic procedures with large, calcified tissue specimens. Olympus's Pneumoliner and the moresolution Morcellator can provide select patients with a laparoscopic surgical option.

Hence, factors such as the rising prevalence of uterine fibroids and the increasing advantages of technologically advanced myomectomy procedures are expected to boost market growth. However, the higher costs of new medical devices and complications associated with the procedure might restrict the growth of the market.

Myomectomy Industry Segmentation

Myomectomy is a surgical procedure to remove fibroids from the uterus. It allows the uterus to be left in place. It is for women who wish to get pregnant after receiving treatment for their fibroids. This procedure is considered the standard of care for removing fibroids and preserving the uterus. 

The myomectomy market is segmented by type, product, end user, and geography. By type, the market is segmented into abdominal, laparoscopic, hysteroscopic, and robotic. By product, the market is segmented into laparoscopic power morcellators, harmonic scalpels, laparoscopic sealers, and others. By end user, the market is segmented into clinics/hospitals and ambulatory surgical centers. By geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD) for all the segments mentioned above.

By Type
Abdominal
Laparoscopic
Hysteroscopic
Robotic
By Product
Laparoscopic Power Morcellators
Harmonic Scalpel
Laparoscopic Sealer
Other Products
By End User
Clinics/Hospitals
Ambulatory Surgical Centers
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Rest of the World
Need A Different Region Or Segment?
Customize Now

Myomectomy Market Size Summary

The myomectomy market is poised for significant growth, driven by the increasing prevalence of uterine fibroids and advancements in surgical technologies. Uterine fibroids, common benign tumors affecting a substantial number of women, often lead to symptoms that necessitate surgical intervention, such as myomectomy. The market is expected to expand as minimally invasive procedures, including laparoscopic and robotic-assisted surgeries, gain popularity due to their benefits like reduced blood loss, shorter hospital stays, and quicker recovery times. These technological advancements are enhancing the quality and efficiency of treatments, thereby boosting market demand. Additionally, strategic activities by key market players, such as product launches and mergers, are anticipated to further propel market growth during the forecast period.

North America is expected to hold a significant share of the myomectomy market, attributed to the high prevalence of uterine fibroids and ongoing technological innovations in surgical procedures. The aging population and the increasing number of women in the age group most affected by fibroids are contributing to the rising demand for myomectomy treatments. Despite the high burden of uterine fibroids, which often lead to surgical interventions, the market faces challenges such as the high costs of new medical devices and potential complications associated with procedures. However, the competitive landscape remains robust, with major players like Medtronic, Stryker Corporation, and Hologic Inc. driving innovation and offering new opportunities for market expansion.

Explore More

Myomectomy Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Number of Patients Suffering from Uterine Fibroids

      2. 1.2.2 Rise in Minimally Invasive Procedures

      3. 1.2.3 Technological Advancements

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost of Medical Devices

      2. 1.3.2 Complications Associated with the Procedure

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Buyers/Consumers

      2. 1.4.2 Bargaining Power of Suppliers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Type

      1. 2.1.1 Abdominal

      2. 2.1.2 Laparoscopic

      3. 2.1.3 Hysteroscopic

      4. 2.1.4 Robotic

    2. 2.2 By Product

      1. 2.2.1 Laparoscopic Power Morcellators

      2. 2.2.2 Harmonic Scalpel

      3. 2.2.3 Laparoscopic Sealer

      4. 2.2.4 Other Products

    3. 2.3 By End User

      1. 2.3.1 Clinics/Hospitals

      2. 2.3.2 Ambulatory Surgical Centers

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Rest of the World

Myomectomy Market Size FAQs

The Myomectomy Market size is expected to reach USD 0.64 billion in 2024 and grow at a CAGR of 8.10% to reach USD 0.93 billion by 2029.

In 2024, the Myomectomy Market size is expected to reach USD 0.64 billion.

Myomectomy Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)